Our study found that the SPOP promoter methylation status can be utilized as an epigenetic biomarker of NSCLC and that the C/EBPα-SPOP signaling pathway can be a potential target for NSCLC prevention and treatment. This evidence concerns the gene SPOP and non-small cell lung carcinoma.